Glycotest is developing a proprietary diagnostics platform based on novel glycoprotein biomarkers that detect subtle biological changes associated with liver disease.
Our technology is designed to identify liver cancer and other serious liver diseases through a simple blood sample, enabling earlier diagnosis, routine surveillance and improved patient outcomes.
Built upon years of scientific research and clinical development, the platform combines proprietary biomarkers, advanced analytical methods and sophisticated algorithms to create a new generation of highly sensitive blood tests.
Earlier Detection Can Transform Patient Outcomes

Liver cancer remains one of the leading causes of cancer-related death worldwide.
Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, can often be treated successfully when diagnosed at an early stage. Unfortunately, many patients are diagnosed only after symptoms develop, when treatment options are significantly more limited.
Cholangiocarcinoma (CCA), the second most common primary liver cancer, presents a similar challenge, with most cases diagnosed at an advanced stage.
Liver fibrosis and cirrhosis also remain difficult to assess using existing non-invasive approaches, with liver biopsy continuing to serve as the clinical reference standard.
At the same time, the number of patients requiring surveillance continues to grow as chronic liver disease and metabolic dysfunction-associated steatohepatitis (MASH/NASH) become increasingly prevalent worldwide.
Together, these challenges highlight the need for more accurate, convenient and accessible blood-based diagnostics.
Glycoprotein Biomarkers
Glycotest’s platform is built around glycoproteins, proteins that carry complex sugar structures known as glycans.
As liver disease develops, these glycan structures undergo distinct and measurable changes. Glycotest has identified proprietary glycoprotein biomarkers that capture these disease-associated changes, creating highly specific biological signatures that can be measured using a standard blood sample.
Unlike conventional diagnostic approaches that often rely on individual biomarkers, Glycotest analyzes multiple complementary disease signals to provide a more complete picture of disease biology.
Measuring Disease Signals
Glycotest’s technology measures two complementary indicators of liver disease.
01
Abnormal Glycan Profiles
Changes in glycan structures on selected serum glycoproteins provide an important indicator of disease.
02
Disease-specific Glycoprotein Patterns
Patterns associated with hepatocellular carcinoma, cholangiocarcinoma and liver fibrosis.
Together, these measurements generate highly informative biological signals that support accurate disease detection and surveillance.
From Blood Sample to Clinical Insight
In healthy individuals, the glycoproteins measured by Glycotest possess normal glycan profiles.
As liver disease develops, these proprietary blood-based biomarkers become increasingly decorated with abnormal glycan profiles.
Using proprietary assay technology, Glycotest measures these changes in a standard blood sample collected from patients living with chronic liver disease. The resulting data are combined with established clinical markers using proprietary algorithms to provide physicians with valuable information that can support earlier clinical decision making.
Blood sample
A simple blood sample is collected from the patient.
Biomarker measurement
Glycan and glycoprotein changes are measured using proprietary assays.
Algorithmic analysis
Data are combined with clinical markers using proprietary algorithms.
Clinical insight
The resulting information can support earlier clinical decision making.
A New Approach to Liver Cancer Surveillance
The HCC Panel is Glycotest’s lead diagnostic program and demonstrates the capabilities of the Company’s broader technology platform.
Designed for the surveillance of patients at increased risk of hepatocellular carcinoma, the HCC Panel combines
- Three proprietary Glycotest glycoprotein biomarkers.
- Three established serum biomarkers.
- Patient age.
- Patient sex.
A proprietary algorithm developed using artificial intelligence and machine learning during model training.
Together, these components generate an HCC likelihood score designed to support routine surveillance through a simple blood test.
In preliminary clinical studies, the HCC Panel has demonstrated up to 95% sensitivity at 90% specificity, outperforming current standard surveillance approaches and existing commercial blood tests.
3 Proprietary Glycotest Glycoprotein Biomarkers
Disease-associated glycoprotein signals
3 Established Serum Biomarkers
Additional biomarker inputs
Patient Age & Sex
Clinical characteristics
Proprietary Algorithm
Integrated multi-parameter analysis
HCC
Panel
Up to
95%
Sensitivity
Up to
90%
Specificity
In preliminary clinical studies, the HCC Panel has demonstrated up to 95% sensitivity at 90% specificity.
A Platform for Liver Disease Diagnostics
Glycotest’s technology has been designed as a platform capable of supporting multiple diagnostic programs across liver disease.

HCC
Hepatocellular Carcinoma (HCC)
Developing highly sensitive blood tests for routine surveillance of patients at increased risk of liver cancer.

CCA
Cholangiocarcinoma (CCA)
Developing blood-based diagnostics for the second most common form of primary liver cancer, where significant unmet clinical need remains.

LIVER FIBROSIS
Liver Fibrosis
Developing non-invasive tests to improve the assessment of liver fibrosis progression, including the identification of intermediate-stage disease.
Together, these programs demonstrate the broader potential of Glycotest’s proprietary biomarker platform.
Second-generation Glycoproteomic Assays
Building on the success of its first-generation assays, Glycotest is advancing a second-generation glycoproteomic assay platform using mass spectrometry.
This next-generation approach enables much more detailed characterisation of glycan structures attached to proprietary biomarkers, generating richer biological information while further enhancing diagnostic performance.
The platform has been developed to maximize performance across today’s expanding non-viral liver disease population while supporting the continued evolution of Glycotest’s diagnostic pipeline.
The Science Behind Our Platform
01
Proprietary diagnostics platform built on novel glycoprotein biomarkers.
02
Measures unique glycan-based disease signals associated with liver disease.
03
Combines proprietary biomarkers with established clinical markers using advanced algorithms.
04
Lead HCC Panel supported by a broader pipeline targeting cholangiocarcinoma and liver fibrosis.
05
Advancing second-generation glycoproteomic assays using mass spectrometry.
06
Protected by an extensive international intellectual property portfolio.
07
Designed to support earlier diagnosis, routine surveillance and improved patient outcomes through simple, non-invasive blood tests.